<DOC>
	<DOCNO>NCT02069717</DOCNO>
	<brief_summary>The purpose study assess incidence rate major adverse cardiovascular event ( MACE ) safety fenofibrate ( Lipilfen capsule ) add-on statin therapy patient history acute myocardial infarction diagnose metabolic syndrome .</brief_summary>
	<brief_title>Observational Study Assess Incidence Rate Major Adverse Cardiovascular Events ( MACE ) Safety Fenofibrate ( Lipilfen Capsule )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>patient &gt; 20 year age . history acute myocardial infarction metabolic syndrome diagnosis current liver disease AST ALT great 3 time upper limit reference range preexist gallbladder disease moderate severe renal disorder ( serum creatinine &gt; 2.5mg/dL ) pancreatitis diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>